Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Although botulinum neurotoxin serotype A (BoNT/A) products are common treatments for various disorders, there is only one commercial BoNT/B product, whose low potency, likely stemming from low affinity toward its human receptor synaptotagmin 2 (hSyt2), has limited its therapeutic usefulness. We expr...

Full description

Saved in:
Bibliographic Details
Published in:Sci Adv
Main Authors: Elliott, Mark, Favre-Guilmard, Christine, Liu, Sai Man, Maignel, Jacquie, Masuyer, Geoffrey, Beard, Matthew, Boone, Christopher, Carré, Denis, Kalinichev, Mikhail, Lezmi, Stephane, Mir, Imran, Nicoleau, Camille, Palan, Shilpa, Perier, Cindy, Raban, Elsa, Zhang, Sicai, Dong, Min, Stenmark, Pål, Krupp, Johannes
Format: Artigo
Language:Inglês
Published: American Association for the Advancement of Science 2019
Subjects:
Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357751/
https://ncbi.nlm.nih.gov/pubmed/30746458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aau7196
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items